Binds Hormone, Lymphokine, Cytokine, Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Intercellular Mediator, Or Neurotransmitter (e.g., Insulin, Human Chorionic Gonadotropin, Glucagon, Cardiodilatin, Interleukin, Interferon, Norepinephrine, Epinephrine, Acetylcholine, Etc.) Patents (Class 530/389.2)
-
Publication number: 20140161817Abstract: The invention provides stable aqueous formulations comprising an Aqueous Stable Dual Variable Domain Immunoglobulin (AS-DVD-Ig) protein. The invention also provides stable lyophilized formulations comprising a Lyophilized Stable Dual Variable Domain Immunoglobulin (LS-DVD-Ig) protein.Type: ApplicationFiled: November 1, 2013Publication date: June 12, 2014Inventors: Michael Siedler, Vineet Kumar, Ravi Chari, Sonal Saluja, Vishwesh Patil
-
Publication number: 20140154255Abstract: The present disclosure relates to antibodies directed to vascular endothelial growth factor (“VEGF”) and uses of such antibodies, for example to treat diseases associated with the activity and/or overproduction of VEGF.Type: ApplicationFiled: November 26, 2013Publication date: June 5, 2014Applicant: AbbVie Biotherapeutics Inc.Inventor: Yoshiko AKAMATSU
-
Publication number: 20140147445Abstract: The CD40L/Mac-1 interaction is selectively targeted by small peptide inhibitors and/or antibodies and such peptides are used for the specific treatment of inflammation and atherogenesis. In particular, pharmaceutical compositions comprising a polypeptide having the amino acid sequence EQLKKSKTL and antibodies specifically binding to an epitope are disclosed.Type: ApplicationFiled: August 17, 2011Publication date: May 29, 2014Applicants: BAKER IDI HEART & DIABETES INSTITUTE HOLDINGS LTD., UNIVERSITATSKLINIKUM FREIBURGInventors: Andreas Zirlik, Dennis Wolf, Karlheinz Peter
-
Publication number: 20140147447Abstract: Compositions and methods are provided for treating diseases associated with CXCL13 expression, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CXCL13 monoclonal antibodies have been developed to neutralize CXCL13.Type: ApplicationFiled: September 1, 2011Publication date: May 29, 2014Applicant: VACCINEX, INC.Inventors: Ekaterina Klimatcheva, Mark Paris, Ernest S. Smith
-
Publication number: 20140147439Abstract: A method of preparing an antibody suitable for use in a feline is provided. Also provided are chimeric and felinised antibodies which specifically bind to feline neuronal growth factor (NGF) and neutralise the ability of feline NGF to bind to the p75 or TrkA feline NGF receptor. The invention extends to nucleic acids encoding same and to methods of treating pain and arthritis in a feline using said antibodies and/or nucleic acids.Type: ApplicationFiled: May 8, 2012Publication date: May 29, 2014Inventor: David Gearing
-
Publication number: 20140148388Abstract: The present invention is directed to novel chimeric fibroblast growth factor (FGF) polypeptides, novel DNA encoding chimeric FGF polypeptides, and to the recombinant production of chimeric FGF polypeptides, and to methods, compositions and assays utilizing chimeric FGF polypeptides for the therapeutic treatment of metabolic-related disorders and other conditions, and for producing pharmaceutically active compositions including chimeric FGF polypeptides, the compositions having therapeutic and pharmacologic properties including those associated with the treatment of metabolic-related disorders and other conditions.Type: ApplicationFiled: August 7, 2013Publication date: May 29, 2014Applicant: GENENTECH, INC.Inventor: Junichiro SONODA
-
Patent number: 8734801Abstract: The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.Type: GrantFiled: October 18, 2011Date of Patent: May 27, 2014Assignee: Genentech, Inc.Inventors: Sek Chung Fung, Matthew Moyle, Mason Lu, Changning Yan, Sanjaya Singh, Dan Huang
-
Patent number: 8734797Abstract: The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.Type: GrantFiled: October 18, 2011Date of Patent: May 27, 2014Assignee: Genentech, Inc.Inventors: Sek Chung Fung, Matthew Moyle, Mason Lu, Changning Yan, Sanjaya Singh, Dan Huang
-
Publication number: 20140141011Abstract: The invention relates to binding compounds that specifically bind to human TSLP, as well as uses thereof, e.g., in the treatment of inflammatory disorders.Type: ApplicationFiled: October 8, 2013Publication date: May 22, 2014Applicant: SCHERING CORPORATIONInventors: LEONARD G. PRESTA, RENE DE WAAL MALEFYT
-
Publication number: 20140141012Abstract: The invention relates to binding compounds that specifically bind to human TSLP, as well as uses thereof, e.g., in the treatment of inflammatory disorders and allergic inflammatory response.Type: ApplicationFiled: January 28, 2014Publication date: May 22, 2014Applicant: MERCK SHARP & DOHME CORP.Inventor: Leonard G. Presta
-
Patent number: 8728469Abstract: A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.Type: GrantFiled: April 11, 2013Date of Patent: May 20, 2014Assignee: ZymoGenetics, Inc.Inventors: Penny Thompson, Hal Blumberg, Yasmin A. Chandrasekher, Julia E. Novak
-
Publication number: 20140134183Abstract: The present invention relates to anti-IL-1 beta binding members and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.Type: ApplicationFiled: November 5, 2013Publication date: May 15, 2014Applicant: Delenex Therapeutics AGInventors: Stefanie Grabulovski, Titus Kretzschmar, Simone Schmitt, Abdijapar Shamshiev
-
Publication number: 20140134237Abstract: The subject invention pertains to agonist peptides of type I interferons and methods of using the peptides. These peptides are based on the amino acid sequence of the C-terminus region of the type I IFN molecules and are capable of binding to the cytoplasmic domain of type I IFN receptors. Surprisingly, these peptides were found to possess the same or similar biological activity as that associated with the full-length, mature type I IFN proteins, even though these peptides do not bind to the extracellular domain of the type I IFN receptors. In one embodiment, the peptide is a peptide of IFN?. In another embodiment, the peptide is a peptide of IFN?. Exemplified peptides of the invention include those having SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:38, SEQ ID NO:39, and SEQ ID NO:40. The subject peptides have been shown to effect increased resistance to viral infection.Type: ApplicationFiled: December 11, 2013Publication date: May 15, 2014Inventors: HOWARD M. JOHNSON, CHULBUL M. AHMED
-
Publication number: 20140134157Abstract: Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.Type: ApplicationFiled: March 14, 2013Publication date: May 15, 2014Applicants: AMGEN FREMONT INC., AMGEN INC.Inventors: Amgen Inc., Amgen Fremont Inc.
-
Publication number: 20140134176Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to PDGF-B. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of PDGF-B mediated diseases, disorders or conditions.Type: ApplicationFiled: November 8, 2013Publication date: May 15, 2014Applicant: Pfizer Inc.Inventors: Robert ARCH, Gregory CARVEN, Jun KUAI, Lydia MOSYAK, Shinji OGAWA, Dirk PONSEL, Robert RAUCHENBERGER
-
Publication number: 20140127230Abstract: The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGF?), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TGF?1, TGF?2 and TGF?3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).Type: ApplicationFiled: October 21, 2013Publication date: May 8, 2014Inventors: Steven R. Ledbetter, Celia Patricia Hart, Robert G. Holgate, Lutz U. Jermutus, Catriona L. Buchanan, Alexander R. Duncan, Donna K. Finch
-
Publication number: 20140112933Abstract: The present invention relates to antibodies against angiopoietins 1 and 2, and derivatives of these antibodies. More specifically, the present invention relates to therapeutic use of the antibodies and fragment thereof which specifically bind to angiopoietins 1 and 2.Type: ApplicationFiled: April 5, 2011Publication date: April 24, 2014Applicant: NeoPharm Co. LTD..Inventors: Eunkyung Lee, Hyunjung Kang, Minhee Kim, Eun hye Park
-
Publication number: 20140112935Abstract: The present disclosure provides antibodies that bind to human interleukin-6 (IL6). The antibodies can modulate IL6 signaling and thus used in treatment or prevention of IL6 associated diseases or disorders, particularly inflammatory disorder, rheumatoid arthritis (RA), angiogenesis, and cancer.Type: ApplicationFiled: October 18, 2013Publication date: April 24, 2014Applicant: Fountain Biopharma Inc.Inventors: Willie Lin, Tong-Young Lee, Han-Chung Wu, Tanny Chen Tsao
-
Publication number: 20140105909Abstract: Described herein are anti-sclerostin antibody crystals, methods of making such antibody crystals and formulations comprising the antibody crystals.Type: ApplicationFiled: March 23, 2012Publication date: April 17, 2014Applicant: AMGEN INC.Inventors: Christi L. Clogston, Twinkle L. Christian, Timothy D. Osslund, Elisabeth Freeman
-
Publication number: 20140099265Abstract: The invention relates to a method and apparatus for pre-hatch avian embryo sex determination. In particular, the invention relates to a non-invasive method and apparatus for in-ovo determining the sex of avian species while in the egg and allowing to sort the eggs into groups consisting primarily of either male or female embryos. The method comprises the steps of introducing into the egg an antibody designed to match with a sex specific antigen on the embryo, which antibody is labelled, allowing the labelled antibody to migrate to and bind with the sex specific antigen on the embryo, detecting binding of the labelled antibodies on the embryo using detection means positioned outside of the egg.Type: ApplicationFiled: December 10, 2013Publication date: April 10, 2014Applicant: VAN DE VEN BEHEER B.V.Inventors: Eddy DECUYPERE, Frank FEY
-
Publication number: 20140100359Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.Type: ApplicationFiled: September 10, 2013Publication date: April 10, 2014Applicant: ABBVIE INC.Inventors: Chengbin WU, Tariq GHAYUR, Richard W. DIXON, Jochen G. SALFELD
-
Patent number: 8691585Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: GrantFiled: June 1, 2011Date of Patent: April 8, 2014Assignee: The Trustees of Columbia University in the City of New YorkInventors: John F. O'Connor, Galina I. Kovalevskaya, Steven Birken
-
Publication number: 20140086913Abstract: Provided are antibodies, including functional antibody fragments, that specifically bind to discoidin domain receptors (DDRs), and in particular to DDR1 proteins, as well as uses and method of using such antibodies, including in the detection, diagnosis and treatment of diseases and conditions associated with DDR1.Type: ApplicationFiled: September 25, 2013Publication date: March 27, 2014Applicant: GILEAD SCIENCES, INC.Inventors: Victoria SMITH, Scott Alan MCCAULEY, Maria VAYSBERG, Joanne I. ADAMKEWICZ
-
Publication number: 20140088296Abstract: The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-1 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.Type: ApplicationFiled: April 25, 2013Publication date: March 27, 2014Applicant: ABBOTT LABORATORIESInventor: ABBOTT LABORATORIES
-
Publication number: 20140086829Abstract: The present invention reveals human recombinant antibodies that recognize the human Vascular Endothelium Growth Factor A (VEGF-A), block its interaction with the VEGFR2 receptor, and interfere with its proliferative effect in vitro and pro-angiogenic effect in vivo. The antibodies identify an epitope on human VEGF-A different from any other previously reported, and were obtained by combining one immunoglobulin light chain variable region with other three heavy chain ones. The antibodies were obtained by human immunoglobulin variable region mutagenesis, and can be employed for the immunotherapy of pathological entities associated with to an increase in vasculature, such as age-related macular degeneration, cancer, and others.Type: ApplicationFiled: December 26, 2011Publication date: March 27, 2014Applicants: BIOREC S.A., CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: Humberto Lamdan Ordas, Jorge Victor Gavilondo Cowley, Marta Ayala Avila, Yasmiana Munoz Pozo, Amaury Pupo Merino, Gertrudis Rojas Dorantes, Lincidio Perez Sanchez
-
Patent number: 8679487Abstract: Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 antagonist to a patient afflicted with such a condition. Suitable IL-4 antagonists include, but are not limited to, IL-4 receptors (such as a soluble human IL-4 receptor), antibodies that bind IL-4, antibodies that bind IL-4R, IL-4 muteins that bind to IL-4R but do not induce a biological response, molecules that inhibit IL-4-induced signal transduction, and other compounds that inhibit a biological effect that results from the binding of IL-4 to a cell surface IL-4R. Particular antibodies provided herein include human monoclonal antibodies generated by procedures involving immunization of transgenic mice. Such human antibodies may be raised against human IL-4 receptor. Certain of the antibodies inhibit both IL-4-induced and IL-13-induced biological activities.Type: GrantFiled: July 1, 2010Date of Patent: March 25, 2014Assignee: Immunex CorporationInventors: Richard J. Armitage, Jose Carlos Escobar, Arvia E. Morris
-
Patent number: 8679489Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.Type: GrantFiled: February 8, 2013Date of Patent: March 25, 2014Assignee: XBiotech, Inc.Inventor: John Simard
-
Publication number: 20140081003Abstract: The present invention relates to methods and compositions for preventing incorporation of norleucine into proteins during recombinant protein production in bacteria. The present invention also provides microorganism host cells and nucleic acid molecules for use with the methods and compositions provided herein.Type: ApplicationFiled: September 19, 2013Publication date: March 20, 2014Applicant: Genentech, Inc.Inventors: Michael W. Laird, Karthik Veeravalli
-
Publication number: 20140079716Abstract: The instant invention is based, at least in part on the identification of a new class of antibodies that result, e.g., in improved LT blocking capabilities. Methods of making the subject binding molecules and methods of using the binding molecules of the invention to antagonize LT?R signaling are also provided.Type: ApplicationFiled: March 14, 2013Publication date: March 20, 2014Applicant: BIOGEN IDEC MA INC.Inventor: BIOGEN IDEC MA INC.
-
Publication number: 20140079719Abstract: An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: ApplicationFiled: November 20, 2013Publication date: March 20, 2014Applicant: Novartis AGInventors: Franco E. Di Padova, Hermann Gram, Hans Hofstetter, Margit Jeschke, Jean-Michel Rondeau, Wim Van Den Berg
-
Patent number: 8673310Abstract: The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNF-mediated disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.Type: GrantFiled: June 25, 2009Date of Patent: March 18, 2014Assignee: ESBA Tech, an Alcon Biomedical Research Unit LLCInventors: Leonardo Borras, Tea Gunde, David Urech
-
Publication number: 20140065143Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.Type: ApplicationFiled: July 24, 2013Publication date: March 6, 2014Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Fuh, Yu Miao
-
Publication number: 20140065163Abstract: The present invention relates to antibodies with specificity for granulocyte-macrophage colony stimulating factor (GM-CSF). More particularly, the invention relates to humanized monoclonal antibodies that bind specifically to human GM-CSF with high affinity. The invention also relates to nucleic acids encoding the antibodies, vectors for expression of these nucleic acids, and host cells for producing said antibodies. Further, the invention relates to the use of said antibodies in the diagnosis or treatment of autoimmune or inflammatory diseases.Type: ApplicationFiled: November 17, 2011Publication date: March 6, 2014Inventors: Laurent Magnenat, Olivier Leger, Charles MacKay, David Georges Zahra
-
Patent number: 8664366Abstract: The present invention refers to fusion proteins comprising a neck region and carbohydrate recognition domain of a collectin trimerization domain, a linker element and an effector polypeptide. Further the invention refers to a nucleic acid encoding the said fusion protein. The fusion proteins, the nucleic acid, and the cell are suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications as described herein.Type: GrantFiled: January 9, 2009Date of Patent: March 4, 2014Assignee: Apogenix GmbHInventors: Oliver Hill, Marcus Branschaedel, Christian Gieffers, Meinolf Thiemann
-
Patent number: 8658771Abstract: The present invention provides humanized anti-human IFN-? monoclonal antibodies useful for therapeutic applications in humans. Preferred antibodies are humanized versions of murine antibodies ACO-1 and ACO-2, as well as variants thereof.Type: GrantFiled: December 19, 2012Date of Patent: February 25, 2014Assignee: Argos Therapeutics, Inc.Inventors: Lars Anders Svensson, Soren Padkjaer, Birgitte Friedrichsen, Berit Olsen Krogh, Inger Lund Pedersen, Jan Fleckner
-
Publication number: 20140050728Abstract: Methods and compositions for modulating cyclophilin D, e.g., at least one cyclophilin D biological activity, are provided. Modulation of cyclophilin D is useful in preventing or treating obesity, an overweight condition, or in accommodating a desire to lose weight as well as being useful in treating a variety of kidney diseases.Type: ApplicationFiled: January 27, 2012Publication date: February 20, 2014Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKAInventor: Babu Padanilam
-
Publication number: 20140044732Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.Type: ApplicationFiled: September 24, 2013Publication date: February 13, 2014Applicant: UCB Pharma S.A.Inventors: Ralph Adams, Andrew George Popplewell, Stephen Edward Rapecki
-
Publication number: 20140044713Abstract: The present invention relates to compounds that act as agonists of the Wnt signalling pathway, compositions comprising these compounds and the uses of these compounds, both therapeutic and in research. The invention also provides methods of identifying compounds that act as agonists of the Wnt signalling pathway.Type: ApplicationFiled: April 16, 2012Publication date: February 13, 2014Applicant: KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPENInventors: Willibrordus Barend Maria De Lau, Johannes Carolus Clevers
-
Publication number: 20140039164Abstract: Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.Type: ApplicationFiled: August 7, 2013Publication date: February 6, 2014Applicants: Medarex, Inc., Amgen Inc.Inventors: Brian Varnum, Chris Vezina, Alison Witte, Xueming Qian, Francis Hall Martin, Haichun Huang, Gary Elliott
-
Publication number: 20140038203Abstract: Methods of detecting or predicting the onset or magnitude of kidney diseases such as acute kidney disease (AKI), previously called acute renal failure (ARF), are provided. In various aspects, methods and kits are provided to detect specific urinary proteins associated with AKI diagnosis or prognosis such as, e.g., angiotensinogen.Type: ApplicationFiled: July 9, 2013Publication date: February 6, 2014Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENTInventors: John ARTHUR, Michael JANECH, Joseph ALGE
-
Patent number: 8642035Abstract: The present invention provides improved antibodies or antigen-binding molecules that specifically recognize and agonize the tyrosine receptor kinase B (TrkB) receptor, and methods of their use. Also provided in the invention are polynucleotides and vectors that encode such molecules and host cells that harbor the polynucleotides or vectors.Type: GrantFiled: January 16, 2009Date of Patent: February 4, 2014Assignee: IRM LLCInventor: Kenneth R. Luehrsen
-
Publication number: 20140030266Abstract: The present invention relates to the discovery that altered levels of D-DT (also known as MIF-2) are associated with disorders and diseases. Thus, the present invention relates to compositions and methods useful of the assessment, diagnosis, characterization, prevention and treatment of disorders and diseases associated with an elevated level of D-DT. The present invention also relates to compositions and methods useful of the assessment, diagnosis, characterization, prevention and treatment of disorders and diseases associated with a reduced level of D-DT.Type: ApplicationFiled: November 23, 2011Publication date: January 30, 2014Applicant: Yale UniversityInventors: Richard J. Bucala, Lawrence H. Young
-
Publication number: 20140023659Abstract: Provided herein are antibodies and methods of using the antibodies to treat and diagnose neurite degenerative diseases and disorders.Type: ApplicationFiled: September 23, 2013Publication date: January 23, 2014Inventors: Bernhard Mueller, Lili Huang, Philip D. Bardwell, Yuliya Kutskova, John Memmott
-
Publication number: 20140023644Abstract: The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGF?), including TGF?1, TGF?2 and TGF?3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGF? expression.Type: ApplicationFiled: September 26, 2013Publication date: January 23, 2014Applicant: XOMA Technology Ltd.Inventors: Daniel Bedinger, Shireen S. Khan, Amer Mirza, Ajay J. Narasimha, Toshihiko Takeuchi
-
Publication number: 20140017256Abstract: The invention relates to batch crystallization methods for crystallizing an anti-hIL-12 antibody that allows the production of the antibody on an industrial scale, antibody crystals obtained according to the methods, compositions containing the crystals, and methods of using the crystals and the compositions.Type: ApplicationFiled: February 7, 2013Publication date: January 16, 2014Applicant: ABBVIE INC.Inventors: David W. Borhani, Wolfgang Fraunhofer, Hans-Juergen Krause, Anette Koenigsdorfer, Gerhard Winter, Stefan Gottschalk
-
Patent number: 8628777Abstract: The present invention is directed to novel polypeptides having homology to the IL-1-like family of proteins and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention, and methods for producing the polypeptides of the present invention.Type: GrantFiled: June 30, 2009Date of Patent: January 14, 2014Assignee: Genentech, Inc.Inventors: Audrey Goddard, Guohua James Pan
-
Publication number: 20140010822Abstract: This invention provides methods and compositions of antibody therapeutics that are therapeutically effective in the digestive tract or below the mucosal barrier of the digestive tract but do not deliver levels of antibody to the systemic circulation that have been shown to be necessary for clinical benefit following systemic administration of antibody. This invention further describes therapeutic compositions of antibody therapeutics that are therapeutically effective in the digestive tract or below the mucosal barrier of the digestive tract but do not deliver levels of antibody to the systemic circulation that have been associated with adverse events and systemic immunosuppression following systemic administration of antibody.Type: ApplicationFiled: August 21, 2013Publication date: January 9, 2014Applicant: Avaxia Biologics, IncorporatedInventors: BARBARA S. FOX, Douglas C. Stafford
-
Publication number: 20140004109Abstract: The present invention relates to a method of reducing the numbers of eosinophils in a human subject comprising administration to a subject an IL-5R binding molecule that comprises (a) a region that specifically binds to the IL-5R and (b) an immunoglobulin Fc region. In a specific embodiment, a method of the invention reduces the number of eosinophils in blood, bone marrow, gastrointestinal tract (e.g. esophagus, stomach, small intestine and colon), or lung.Type: ApplicationFiled: July 3, 2013Publication date: January 2, 2014Applicants: Medlmmune, LLC, Biowa, Inc.Inventors: Masamichi Koike, George L. SPITALNY, Alistair WHEELER, Barbara WHITE
-
Publication number: 20140004127Abstract: This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-?) and methods for treating IFN-? mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-?. Methods of detecting the amount of IFN-? in a sample using antibodies to IFN-? are also provided.Type: ApplicationFiled: August 13, 2013Publication date: January 2, 2014Applicants: MEDAREX, INC., AMGEN INC.Inventors: Andrew A. Welcher, Hilary T. Chute, Yue-Sheng Li, Haichun Huang
-
Publication number: 20140004125Abstract: An IL-1? binding antibody or IL-1? binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 2, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease, and a method of preparing an affinity matured IL-1? binding polypeptide. IL-1? binding antibodies or IL-1? binding fragments thereof are provided which have desirable affinity and potency.Type: ApplicationFiled: January 11, 2013Publication date: January 2, 2014Applicant: XOMA TECHNOLOGY LTD.Inventor: Xoma Technology Ltd.